Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aardvark reported a Q2 net loss of $14.4 million with cash and investments totaling $73.9 million, which management believes supports operations into late 2027. The company announced it terminated the Phase 3 HERO and OLE trials for ARD-101 following a full FDA clinical hold placed on the IND in May 2026.
Key figures
- Runway
- late 2027
- Net loss
- 14400000
- Ga expenses
- 4600000
- Rd expenses
- 10500000
- Cash position
- 73900000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.